🔍 Nkarta, Inc. (NKTX) Proxy Statement Breakdown

This document is a Definitive Proxy Statement (DEF 14A) for Nkarta's 2026 Annual Meeting of Stockholders. It outlines proposals for stockholders to vote on and provides essential company governance, director nominations, and executive compensation details.

🧾 What This Document Is & Why It Exists

• Type: DEF 14A - A formal notice sent to shareholders before the annual meeting.
• Purpose: To officially inform shareholders about meeting details, proposals, director nominees, compensation, and governance so they can vote.
• What to Expect: Details on voting, board composition, pay, audits, and related transactions.

🏢 What The Company Does (In Simple Terms)

• Nkarta is a clinical-stage biopharmaceutical company focused on developing cell therapies.
• Mission: They engineer immune cells (like NK cells) to target and kill cancer cells.
• Industry: Highly innovative but risky biotech sector, requiring significant R&D investment before potential products generate revenue.

👥 Who's Running the Show? (Governance & Directors)

• Board Structure: 8 directors divided into 3 classes with staggered 3-year terms.
• Key Proposal 1 (Election): Stockholders will vote to elect Ali Behbahani and Zachary Scheiner as Class III directors to serve until 2029.
  • Dr. Behbahani (Chairman): Partner at New Enterprise Associates (VC firm), extensive board experience in biotech.
  • Dr. Scheiner: Partner at RA Capital Management (healthcare investment firm), science background.
• Board Independence: The Board determined 7 out of 8 directors are "independent" (CEO Paul Hastings is the exception).
• Committees: Four key board committees oversee specific areas:
  • Audit: Oversees finances & accounting (Leone Patterson is Chair & "financial expert").
  • Compensation: Sets executive pay (Michael Dybbs is Chair).
  • Nominating & Governance: Finds director candidates & oversees governance (Ali Behbahani is Chair).
  • Science & Technology: Reviews R&D pipeline & strategy (Angela Thedinga & George Vratsanos are Co-Chairs).

💰 Executive Compensation (How Much & How)

• Named Executive Officers (NEOs) for 2025: Paul Hastings (CEO), Nadir Mahmood (President), Shawn Rose (CMO).
• Compensation Philosophy: Mix of base salary, annual cash bonuses (tied to goals), and long-term equity (stock options & RSUs) to align with shareholder interests.
• Key Numbers (2025 Total Compensation):
  • Paul Hastings (CEO): ~$2.98 million
  • Nadir Mahmood (President): ~$1.40 million
  • Shawn Rose (CMO): ~$1.22 million (joined June 2025)
• Equity Grants (2025): Significant stock options granted to executives in 2025, including a special retention grant in June 2025 (post-reduction in force).
• Outstanding Equity: Detailed tables show unvested options and RSUs held by NEOs as of Dec 31, 2025, representing future potential value.
• Proposal 3 (Advisory Vote): Stockholders will cast a non-binding vote approving the NEO compensation ("Say on Pay").

💸 Cash & Financial Health (The Basics)

• 2025 Annual Report: Referenced as available, but specific financials (revenue, cash, net loss) are not summarized in this proxy statement (they'd be in the 10-K/Annual Report).
• Cash Flow Context: The proxy mentions a reduction in force (RIF) in March 2025, signaling cost management efforts typical for clinical-stage biotechs focused on preserving cash for R&D.

⚖️ Key Relationships & Potential Conflicts

• Related Party Transactions: The Audit Committee reviews transactions involving directors, executives, or major shareholders.
  • RA Ventures (Carnot Pharma): Affiliated with >5% holder RA Capital (Dr. Scheiner's firm) - provided ~$152k in consulting services.
  • March 2024 Stock Offering: Several major investment funds affiliated with Board members participated significantly:
    • RA Capital (Dr. Scheiner): $60 million
    • Samsara BioCapital (Dr. Dybbs): $9 million
    • SR One (Dr. George): $20 million
• Proposal 2 (Auditor): Ratify Ernst & Young LLP as the independent auditor for 2026.

🔮 What's Next? (Meeting & Voting)

• Meeting: Virtual Only on June 10, 2026, at 1:00 PM Pacific Time.
• Record Date: Shareholders owning stock on April 17, 2026, can vote.
• Voting Items:
  1. Elect Directors: Behbahani & Scheiner (Board Recommends: FOR ALL).
  2. Ratify Auditor: Ernst & Young LLP (Board Recommends: FOR).
  3. Approve Executive Pay (Advisory): (Board Recommends: FOR).
  4. Set Frequency of Future Pay Votes: (Board Recommends: 1 YEAR).
• Deadline for 2027 Proposals: December 24, 2026 (for inclusion in proxy); March 12, 2027 (for other nominations/proposals).

🧠 The Analogy

Think of this proxy statement as a mandatory "owner's manual & report card" sent to the owners (shareholders) of a high-tech R&D company (Nkarta) before their annual meeting. It tells them: 1) Who is on the board overseeing things, 2) How much the top engineers and the CEO are being paid, 3) Who checks the books, and 4) Exactly what decisions they need to vote on to keep the company running according to its rules.

🧩 Final Takeaway

Nkarta is holding its annual shareholder meeting where key votes include re-electing two experienced directors, approving executive pay, and ratifying its auditor. The filing reveals significant involvement and investment from directors' affiliated venture capital firms (RA Capital, Samsara, SR One), which is common in biotech but requires shareholder awareness. The focus remains on R&D progress while managing cash after a 2025 workforce reduction.